Barcellos-Hoff Mary Helen, Akhurst Rosemary J
New York University Langone School of Medicine, New York, NY 10016, USA.
Breast Cancer Res. 2009;11(1):202. doi: 10.1186/bcr2224. Epub 2009 Feb 26.
The contribution of transforming growth factor (TGF)beta to breast cancer has been studied from a myriad perspectives since seminal studies more than two decades ago. Although the action of TGFbeta as a canonical tumor suppressor in breast is without a doubt, there is compelling evidence that TGFbeta is frequently subverted in a malignant plexus that drives breast cancer. New knowledge that TGFbeta regulates the DNA damage response, which underlies cancer therapy, reveals another facet of TGFbeta biology that impedes cancer control. Too much TGFbeta, too late in cancer progression is the fundamental motivation for pharmaceutical inhibition.
自二十多年前的开创性研究以来，人们从无数角度研究了转化生长因子（TGF）β对乳腺癌的作用。尽管TGFβ在乳腺中作为典型的肿瘤抑制因子的作用是毫无疑问的，但有令人信服的证据表明，TGFβ在驱动乳腺癌的恶性网络中经常被颠覆。TGFβ调节DNA损伤反应这一癌症治疗基础的新知识，揭示了TGFβ生物学阻碍癌症控制的另一个方面。在癌症进展过程中TGFβ过多、过晚是药物抑制的根本动机。
